NCT01948960 - Influence of Exceptional Patient Characteristics on Everolimus Exposure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

January 15, 2018

Study Completion Date

January 15, 2018

Conditions

Breast Neoplasms

Interventions

DRUG

everolimus dose escalation

patients with an AUC below mean will have dose escalation of everolimus based on their AUC

Trial Locations (7)

Maasziekenhuis Pantein, Boxmeer

Spaarne Gasthuis, Hoofddorp

Maastricht University Medical Center, Maastricht

St. Antonius Ziekenhuis, Nieuwegein

Radboud university medical center, Nijmegen

Bernhoven Ziekenhuis, Uden

Isala Klinieken, Zwolle